Free tool
FAERS Monitor: Levetiracetam In Sodium Chloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202543 or its brand name (Levetiracetam In Sodium Chloride, Levetiracetam). Reports on generic versions are filed under their own applications.
Reports
78,636
Serious
69,598
89% of reports
Hospitalization
28,879
Death reported
7,204
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective9,213
- seizure8,983
- off label use6,638
- maternal exposure during pregnancy3,194
- epilepsy2,826
- foetal exposure during pregnancy2,642
- drug interaction2,532
- fatigue2,500
- condition aggravated2,341
- somnolence2,130
- status epilepticus2,102
- generalised tonic-clonic seizure2,051
- toxicity to various agents1,890
- fall1,864
- dizziness1,783
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 87 |
| 2005 | 118 |
| 2006 | 93 |
| 2007 | 161 |
| 2008 | 212 |
| 2009 | 665 |
| 2010 | 685 |
| 2011 | 994 |
| 2012 | 1,435 |
| 2013 | 1,616 |
| 2014 | 1,555 |
| 2015 | 2,386 |
| 2016 | 3,296 |
| 2017 | 4,570 |
| 2018 | 7,115 |
| 2019 | 7,970 |
| 2020 | 6,820 |
| 2021 | 6,805 |
| 2022 | 6,133 |
| 2023 | 6,861 |
| 2024 | 7,538 |
| 2025 | 6,507 |
| 2026 | 5,011 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,975,523 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| status epilepticusSignal | 2,102 | 60.9 | 58.2 | 100,891 |
| generalised tonic-clonic seizureSignal | 2,051 | 37.7 | 36.0 | 64,210 |
| epilepsySignal | 2,826 | 27.1 | 26.1 | 64,642 |
| seizureSignal | 8,983 | 22.5 | 22.0 | 170,879 |
| maternal exposure during pregnancySignal | 3,194 | 9.9 | 9.6 | 24,750 |
| foetal exposure during pregnancySignal | 2,642 | 9.0 | 8.6 | 18,118 |
| drug interactionSignal | 2,532 | 4.3 | 4.2 | 6,407 |
| toxicity to various agentsSignal | 1,890 | 3.0 | 2.9 | 2,544 |
| somnolenceSignal | 2,130 | 2.8 | 2.7 | 2,551 |
| condition aggravatedSignal | 2,341 | 2.1 | 2.0 | 1,298 |
| off label useSignal | 6,638 | 2.0 | 2.0 | 3,620 |
| drug ineffective | 9,213 | 1.9 | 1.8 | 3,991 |
| fall | 1,864 | 1.5 | 1.4 | 314 |
| dizziness | 1,783 | 1.0 | 0.9 | 4 |
| fatigue | 2,500 | 0.9 | 0.8 | 60 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.